(0.86%) 5 248.49 points
(1.22%) 39 760 points
(0.51%) 16 400 points
(1.30%) $82.41
(1.05%) $1.736
(1.70%) $2 227.90
(-0.12%) $24.72
(0.87%) $917.60
(0.16%) $0.925
(0.48%) $10.82
(-0.03%) $0.791
(0.39%) $92.80
@ $6.41
Issued: 14 Feb 2024 @ 14:41
Return: 44.00%
Previous signal: Feb 14 - 13:57
Previous signal:
Return: 2.72 %
Live Chart Being Loaded With Signals
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology...
Stats | |
---|---|
Today's Volume | 44 760.00 |
Average Volume | 2.08M |
Market Cap | 1.37B |
EPS | $0 ( 2024-03-11 ) |
Next earnings date | ( $-0.180 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -9.05 |
ATR14 | $0.0190 (0.21%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-26 | Summer Road Llc | Buy | 930 851 | Common Stock, $0.0001 par value per share |
2024-02-22 | Dugel Pravin | Buy | 1 282 469 | Stock Option (Right to Buy) |
2024-02-22 | Dugel Pravin | Buy | 854 979 | Common Stock |
2024-02-22 | Nayak Sanjay | Buy | 244 550 | Stock Option (Right to Buy) |
2024-02-22 | Nayak Sanjay | Buy | 80 300 | Common Stock |
INSIDER POWER |
---|
97.63 |
Last 98 transactions |
Buy: 9 847 283 | Sell: 256 052 |
Volume Correlation
Ocular Therapeutix Inc Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Ocular Therapeutix Inc Correlation - Currency/Commodity
Ocular Therapeutix Inc Financials
Annual | 2023 |
Revenue: | $58.44M |
Gross Profit: | $53.16M (90.96 %) |
EPS: | $-0.940 |
Q4 | 2023 |
Revenue: | $14.80M |
Gross Profit: | $13.42M (90.64 %) |
EPS: | $-0.350 |
Q3 | 2023 |
Revenue: | $14.95M |
Gross Profit: | $13.57M (90.79 %) |
EPS: | $-0.00610 |
Q2 | 2023 |
Revenue: | $15.19M |
Gross Profit: | $13.88M (91.41 %) |
EPS: | $-0.260 |
Financial Reports:
No articles found.
Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators